Myriad Genetics co-founder Walter Gilbert PhD bought $150K of MYGN on Dec. 13 @ $25.60. Gilbert, who won the Nobel Prize for Chemistry in 1980, has a history of Form 4 filings at Myriad dating back to 2006. However, this is the insider's first open market purchase...
RA Capital has outperformed all other healthcare hedge funds over the past decade, based on 13F holdings. In fact, RA's 30.88% annualized return of it's equal-weighted top 20 long portfolio led all other hedge funds over that period. So, when RA manager Peter Kolchinsky discloses portfolio changes,...
Engine Capital filed a 13D on Cymabay (CBAY) two weeks after the development stage biotech company halted a trial of its leading drug candidate causing it's shares to fall as much as 75%. In a 13D filing Thursday evening, New York-based Engine Capital, L.P....
Protagonist Therapeutics insiders bought on Tuesday as their company's stock plummeted after preliminary data appeared to cast doubt on Protagonist's (PGTX) key drug. On Monday, the company presented an initial look at preliminary results from the TRANSCEND Ph2 open-label study of PTG-300 (hepcidin...
Engine Capital filed a 13D targeting PDL BioPharm (PDLI) on Wednesday morning, disclosing a 5.28% stake in the Nevada-based healthcare stock. Engine also disclosed it sent a letter to PDLI's board saying the fund "invested in PDLI because of the significant intrinsic value attributable to...
Solid Biosciences' private placement featured investments by an all star list of top biotech institutional investors. Cambridge-based Solid Biosciences (SLDB) trades at 1/3 of its January 2018 IPO value. But based on the A-list biotech investors buying shares in the company's July 26 $60...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...
In the investing world, those with superior information usually make the most money. And possibly no group has better information on public companies – and profitably acts on it – than corporate insiders at small-cap biotech and medical technology companies.